Table 2.
HDI classification by chemical structure and clinical trial use.
| Classification by chemical structure | Named examples (INN) | HDAC specificity | Clinical trial stage |
|---|---|---|---|
| Hydroxamates | SAHA (vorinostat) | Pan‐inhibitor | Approved for CTCL, phase III alone or in combination |
| PXD101 (belinostat) | Pan‐inhibitor | Phase II alone or in combination | |
| LBH589 (panobinostat) | Classes I and II | Phase III alone or in combination | |
| ITF2357 (givinostat) | Pan‐inhibitor | Phase II alone or in combination | |
| 4SC‐201 (resminostat) | Pan‐inhibitor | Phase II alone or in combination | |
| PCI 24781 (abexinostat) | Classes I and II | Phase II alone or in combination | |
| Cyclic peptides | Depsipeptide/FK228 (romidepsin) | Class I | Approved for CTCL and PCTL, phase III alone or in combination |
| Benzamides | MS‐275 (entinostat) | Class I | Phase II alone or in combination |
| MGCD0103 (mocetinostat) | Class I | Phase II alone or in combination | |
| Aliphatic fatty acids | Valproic acid | Classes I and IIa | Phase II alone or in combination |
| Butyrate | Classes I and IIa | Phase II alone or in combination |